1. Department of Pharmacy, Tianjin First Central Hospital, Tianjin 300192, China; 2. Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai 200040, China; 3. Department of Military Pharmacy, Logistics College of Chinese People��s Armed Police Forces, Tianjin 300309, China
Abstract��Tacrolimus is widely used as a first-line immunosuppressant after adult liver transplantation. However, because of narrow treatment window and pharmacokinetic individual differences, it is difficult to formulate individualized dosing regimens in short term. Pharmacokinetic parameters that estimated by population pharmacokinetics(PPK) can provide a preliminary individualized regimen for early postoperative patients. This paper collected literatures on PPK modeling of orally administered tacrolimus in adult liver transplantation patients through literature search. And multiple influencing factors of PPK model was mainly summarized, such as demographic characteristics, blood biochemical index, combined medication, liver and kidney function, genetic factors, postoperative time and dosage. It will provide literature support for the development of individualized dosing regimens for oral tacrolimus recipients using the PPK protocol for adult liver transplantation.
ZHENG S, YU J, ZHANG W. Current development of liver transplantation in China. J Clin Hepatol (�ٴ��ε�����־), 2014, 30(1):2-4.
[2]
HADDAD L, ANDRADE K, MENDES L, et al. Association between readmission after liver transplant and adverse immunosuppressant reactions: a prospective cohort with a 1-year follow-up. Transplant Proc, 2017,49(2):330-337.
[3]
FDA. Guidance for Industry Population Pharmacokinetics. 1999, http://www. fda. gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072137. pdf
[4]
CFDA. Circular of General Administration on guiding principles for general consideration of drug clinical trials. . http://www.sda.gov.cn/WS01/CL0087/168752.html.
[5]
SHAO J, JIAO Z, DING J, et al. Bibliometric analysis and research status summary for pharmacometrics in China. Chin J Hosp Pharm(�й�ҽԺҩѧ��־), 2018, 38 (7):687-692.
[6]
LI Y X, LI S J, ZHANG Y, et al. Progress in the application and pharmacokinetics of tacrolimus in pediatric living donor liver transplantation. Tianjin Pharm(���ҩѧ), 2017,29(4):54-57.
[7]
LU Y X, SU Q H, WU K H, et al. A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. Acta Pharmacol Sin(�й�ҩ��ѧ��), 2015, 36(2):281-288.
[8]
MOES D J A, VAN DER BENT S A, SWEN J J, et al. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. Eur J Clin Pharmacol, 2016, 72(2):163-174.
[9]
ZHU L, WANG H, SUN X, et al. The population pharmacokinetic models of tacrolimus in Chinese adult liver transplantation patients. J Pharm (Cairo), 2014, 2014(5-6):713650.
[10]
LING J, QIAN L, DING J, et al. Effects of multiple-trough sampling design and algorithm on the estimation of population and individual pharmacokinetic parameters. Acta Pharm Sin(ҩѧѧ��), 2014, 49(5):686-694.
[11]
SAM W J, THAM L S, HOLMES M J, et al. Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. Clin Pharmacokinet, 2006, 45 (1):59-75.
[12]
OTEO I, LUKAS J C, LEAL N, et al. Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. Eur J Clin Pharmacol, 2013, 69(1):65-74.
[13]
ZAHIR H, MCLACHLAN A J, NELSON A, et al. Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit, 2005, 27(4):422-430.
[14]
ZHANG X Q, WANG Z W, FAN J W, et al. The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients. Ther Drug Monit, 2012, 34(2):126-133.
[15]
KELLY A B, BRIAN D, JVLIA M B, et al. Clinical Pharmacogenetics Implementation Consortium(CPIC) Guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther, 2015,98(1):19-24.
[16]
ZHU L, YANG J, ZHANG Y, et al. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of tacrolimus in Chinese adult liver transplant patients. Xenobiotica, 2015, 45(9):840-846.
[17]
LI D, LU W, ZHU J Y, et al. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther, 2007, 32(5):505-515.
[18]
CHEN C, ZHANG Y, HE X, et al. Interpretation of tacrolimus guidelines for individualized medication. J Med Postgra(ҽѧ�о���ѧ��), 2017, 30(4):342-347.
[19]
ZHENG H X, WEBBER S, ZEEVI A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant, 2015, 3(4):477-483.
[20]
FUKATSU S, YANO I, IGARASHI T, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol, 2001, 57(6-7):479-484.
[21]
FUKUDO M, YANO I, FUKATSU S, et al. Forecasting of blood tacrolimus concentrations based on the bayesian method in adult patients receiving living-donor liver transplantation. Clin Pharmacokinet, 2003, 42(13):1161-1178.
[22]
ANTIGNAC M, HULOT J S, BOLESLAWSKI E, et al. Population pharmacokinetics of tacrolimus in full liver transplant patients:modelling of the post-operative clearance. Eur J Clin Pharmacol, 2005, 61(5-6):409-416.
[23]
LEE J Y, HAHN H J, SON I J, et al. Factors affecting the apparent clearance of tacrolimus in korean adult liver transplant recipients. Pharmacotherapy, 2006, 26(8):1069-1077.
[24]
CHEN L, CHEN R, HUANG S, et al. Population pharmacokinetics of isoniazid in Chinese tuberculosis patients. Chin Pharm J (�й�ҩѧ��־), 2017, 52 (24):2185-2191.
[25]
LI J, LIU Y, TANG L, et al. Population pharmacokinetics of vancomycin in Chinese neonates. Chin Pharm J(�й�ҩѧ��־), 2017, 52 (16):1434-1441.
2018, Vol. 53 
